HX
HXBM.US Helix BioMedix Inc
- Market cap
- USD 739K
- P/E
- -
- P/B
- 4.32x
- ROE
- -35.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is HXBM.US undervalued?
Graham numberThe Graham number of Helix BioMedix Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Helix BioMedix Inc fundamental analysis
No fundamental analysis for Helix BioMedix Inc yet.
Helix BioMedix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Helix BioMedix Inc
Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies. The company was founded in 1988 and is based in Bothell, Washington.
Full company profileHelix BioMedix Inc financial statements
Helix BioMedix Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2011 | 2012 | 2013 | 2014 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.89M | 2.02M | 1.77M | 1.82M | 1.84M | 2.37M | 1.75M | 998K | 804K | 807K |
| Gross Profit | 1.05M | 1.39M | 1.45M | - | 1.73M | 1.93M | 1.74M | 988K | 798K | 802K |
| Operating Income | -2.40M | - | - | - | -1.23M | -1.32M | -1.08M | -984K | -1.06M | -596K |
| EBITDA | -2.30M | - | - | - | -1.19M | -995K | -1.18M | -1.05M | -976K | -546K |
| Net Income | -2.49M | - | - | - | -1.85M | -1.36M | -1.19M | -1.06M | -982K | -552K |
| EPS | -15 | - | - | - | -9.03 | -6.05 | -5.31 | -4.70 | -4.37 | -2.45 |
| Balance Sheet | ||||||||||
| Total Assets | 2.97M | 1.14M | 2.26M | - | 5.64M | 4.84M | 3.93M | 3.03M | 2.21M | 1.68M |
| Total Liabilities | 439K | 1.02M | 202K | - | 3.40M | 108K | 126K | 66.9K | 128K | 138K |
| Shareholders' Equity | 2.54M | 117K | 2.06M | - | 2.24M | 4.73M | 3.80M | 2.96M | 2.08M | 1.54M |
| Cash & Short-term Investments | 1.69M | 334K | 1.52M | - | 4.87M | 4.16M | 3.43M | 2.57M | 1.87M | 1.27M |
| Total Debt | - | - | - | - | 2.92M | - | 71.2K | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.30M | - | - | - | -667K | -855K | -728K | -870K | - | -601K |
| Capital Expenditure | 2.67K | 11.0K | 0.00 | - | 41.1K | 7.60K | 1.35K | 1.32K | - | 3.00 |
| Free Cash Flow | -2.30M | - | - | - | -708K | -862K | -729K | -872K | - | -601K |
| Ratios | ||||||||||
| ROE | -98.2% | - | - | - | -82.8% | -28.8% | -31.3% | -35.7% | -47.1% | -35.8% |
| ROA | -83.7% | - | - | - | -32.9% | -28.1% | -30.3% | -34.9% | -44.4% | -32.9% |
| Net Profit Margin | -131.6% | - | - | - | -101.0% | -57.3% | -67.9% | -105.8% | -122.1% | -68.3% |
| Debt to Equity | - | - | - | - | 1.30x | - | 0.02x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Helix BioMedix Inc dividends
Helix BioMedix Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:300 on Jan 3, 2013.
Who owns Helix BioMedix Inc
Ownership data of Helix BioMedix Inc is not available yet.
Helix BioMedix Inc company profile
- Company name
- Helix BioMedix Inc
- Ticker
- HXBM.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 19125 Northcreek Parkway, Bothell, WA, United States, 98011
- Phone
- 425 402 8400
- Website
- helixbiomedix.com
About Helix BioMedix Inc
Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies. The company was founded in 1988 and is based in Bothell, Washington.
Helix BioMedix Inc management
1- Ms. Robin L. CarmichaelPresident, CEO & Chairman · born 1957